Data from EVAPORATE, presented at the 2019 American Heart Association Scientific Sessions, may be the start of answering a question that has baffled the research community: just how does icosapent ethyl, sold as Vascepa, prevent heart attacks in patients with high triglycerides?
Early data from a study examining how a purified fish oil pill reduces cardiovascular (CV) events suggest that it helps slow the advance of various coronary plaques that increase the risk of heart attacks.
Data from EVAPORATE, presented Monday at the 2019 American Heart Association (AHA) Scientific Sessions in Philadelphia, Pennsylvania, may be the start of answering a question that has baffled the research community: Just how does icosapent ethyl, sold as Vascepa, prevent heart attacks in patients with high triglycerides?
While the study’s primary end point—reduced progression of a dangerous, fatty substance called low attenuation plaque, measured with a computed tomography angiogram—had not reached statistical significance, a commentator at the 2019 AHA Scientific Sessions noted that the data presented are an interim analysis, and “it’s very early.”
A year ago, results from REDUCE-IT trial dazzled attendees at the AHA Sessions: Icosapent ethyl, sold by Amarin as Vascepa since 2012 to treat high triglycerides, was shown to reduce CV events by 25%. Follow-up data released in March showed that the 4-g daily dose reduced first and future events by 30%, and last week an FDA advisory committee voted unanimously to support Amarin’s request for a cardiovascular indication for the pill.
Except, as AHA moderator Donald Lloyd-Jones, MD, ScM, noted, “We still don’t really understand yet how that drug works.”
And that’s the point of EVAPORATE. Matthew Budoff, MD, professor of medicine at UCLA School of Medicine, said this is a “mechanistic study,” to understand how REDUCE-IT produced its findings. By measuring patients’ plaque levels before, during, and at the end of the 18-month period, researchers hope to gain insights on how icosapent ethyl works alongside statins.
Nine months into EVAPORATE—the midway point of the trial—patients taking icosapent ethyl have reduced the advance of low attenuation plaque by 21% compared with those taking placebo; however, the difference showed a P value of .469.
Several secondary plaque measures have reached significance. Compared with placebo, those taking icosapent ethyl have seen the following reductions in plaque progression:
The interim data show an increase in fibrofatty plaque, but also not at the level of statistical significance (P = .650).
Commentator Stephen Nicholls of Monash University in Australia noted that the small size of EVAPORATE—just 80 patients—means it will be critical to keep track of all the participants to yield a meaningful result. He said more clinical trials will be needed.
It’s clear so far that reduction of triglycerides on its own is not producing the dramatic drop in CV events, Nicholls said. This raises the question of whether other patient groups should be taking icosapent ethyl.
The fact that EVAPORATE has not yet met its primary end point is not a cause for worry. “I don’t see this as a failed study,” he said.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More